Implications of COVID-19 infection on patients with uveitis under biologic treatment
Background/aimsTo investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.MethodsIn this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 inf...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2022-11, Vol.106 (11), p.1538-1541 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1541 |
|---|---|
| container_issue | 11 |
| container_start_page | 1538 |
| container_title | British journal of ophthalmology |
| container_volume | 106 |
| creator | AlBloushi, Abdulrahman F Alfawaz, Abdullah M Abu El Asrar, Ahmed M |
| description | Background/aimsTo investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.MethodsIn this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020.ResultsA total of 59 patients were identified. Behçet’s disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension.ConclusionUveitis patients under biologic therapy can be silent carriers for COVID-19. |
| doi_str_mv | 10.1136/bjophthalmol-2020-318577 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8098233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2728715025</sourcerecordid><originalsourceid>FETCH-LOGICAL-b537t-8f1d2767cd8ecef7ecb09923021ce9da193d915601f160ea59dd99d913c592f93</originalsourceid><addsrcrecordid>eNqVkVFr2zAUhUVZWbJ0f6EI9uxOV6ot6WUwsrULFPLS9lXIstwo2JYnyS3791VImrVPpSAQuvrOuQcOQhjIBQCrvtdbP27SRne97wpKKCkYiJLzEzSHy0rkEZef0JwQwguACmboS4zb_KQV8M9oxphkwEQ1R7erfuyc0cn5IWLf4uX6fvWrAInd0FqzG-N8xgzYIUX85NIGT4_WJRfxNDQ24Nr5zj84g1OwOvUZO0Onre6i_Xq4F-ju6vft8k9xs75eLX_eFHXJeCpECw3lFTeNsMa23JqaSEkZoWCsbDRI1kgoKwItVMTqUjaNlHnETClpK9kC_dj7jlPd28bk1UF3agyu1-Gf8tqptz-D26gH_6gEkYIylg2-HQyC_zvZmNTWT2HImRXlVHAoCS0zJfaUCT7GYNvjBiBq14d63Yfa9aH2fWTp-euER-FLARlge6Dutx-xvfyvOkZ-V_YMy0Wt7A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728715025</pqid></control><display><type>article</type><title>Implications of COVID-19 infection on patients with uveitis under biologic treatment</title><source>PubMed Central</source><creator>AlBloushi, Abdulrahman F ; Alfawaz, Abdullah M ; Abu El Asrar, Ahmed M</creator><creatorcontrib>AlBloushi, Abdulrahman F ; Alfawaz, Abdullah M ; Abu El Asrar, Ahmed M</creatorcontrib><description>Background/aimsTo investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.MethodsIn this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020.ResultsA total of 59 patients were identified. Behçet’s disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension.ConclusionUveitis patients under biologic therapy can be silent carriers for COVID-19.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2020-318577</identifier><identifier>PMID: 33931386</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Age ; Biological products ; Body mass index ; Clinical Science ; Coronaviruses ; COVID-19 ; Disease transmission ; immunology ; infection ; Infections ; Inflammation ; Medical supplies ; Monoclonal antibodies ; Ophthalmology ; Pandemics ; Patients ; Sarcoidosis</subject><ispartof>British journal of ophthalmology, 2022-11, Vol.106 (11), p.1538-1541</ispartof><rights>Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage</rights><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b537t-8f1d2767cd8ecef7ecb09923021ce9da193d915601f160ea59dd99d913c592f93</citedby><cites>FETCH-LOGICAL-b537t-8f1d2767cd8ecef7ecb09923021ce9da193d915601f160ea59dd99d913c592f93</cites><orcidid>0000-0003-1104-9208 ; 0000-0003-2226-8617</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098233/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098233/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33931386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>AlBloushi, Abdulrahman F</creatorcontrib><creatorcontrib>Alfawaz, Abdullah M</creatorcontrib><creatorcontrib>Abu El Asrar, Ahmed M</creatorcontrib><title>Implications of COVID-19 infection on patients with uveitis under biologic treatment</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><addtitle>Br J Ophthalmol</addtitle><description>Background/aimsTo investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.MethodsIn this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020.ResultsA total of 59 patients were identified. Behçet’s disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension.ConclusionUveitis patients under biologic therapy can be silent carriers for COVID-19.</description><subject>Age</subject><subject>Biological products</subject><subject>Body mass index</subject><subject>Clinical Science</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Disease transmission</subject><subject>immunology</subject><subject>infection</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Medical supplies</subject><subject>Monoclonal antibodies</subject><subject>Ophthalmology</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Sarcoidosis</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkVFr2zAUhUVZWbJ0f6EI9uxOV6ot6WUwsrULFPLS9lXIstwo2JYnyS3791VImrVPpSAQuvrOuQcOQhjIBQCrvtdbP27SRne97wpKKCkYiJLzEzSHy0rkEZef0JwQwguACmboS4zb_KQV8M9oxphkwEQ1R7erfuyc0cn5IWLf4uX6fvWrAInd0FqzG-N8xgzYIUX85NIGT4_WJRfxNDQ24Nr5zj84g1OwOvUZO0Onre6i_Xq4F-ju6vft8k9xs75eLX_eFHXJeCpECw3lFTeNsMa23JqaSEkZoWCsbDRI1kgoKwItVMTqUjaNlHnETClpK9kC_dj7jlPd28bk1UF3agyu1-Gf8tqptz-D26gH_6gEkYIylg2-HQyC_zvZmNTWT2HImRXlVHAoCS0zJfaUCT7GYNvjBiBq14d63Yfa9aH2fWTp-euER-FLARlge6Dutx-xvfyvOkZ-V_YMy0Wt7A</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>AlBloushi, Abdulrahman F</creator><creator>Alfawaz, Abdullah M</creator><creator>Abu El Asrar, Ahmed M</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1104-9208</orcidid><orcidid>https://orcid.org/0000-0003-2226-8617</orcidid></search><sort><creationdate>20221101</creationdate><title>Implications of COVID-19 infection on patients with uveitis under biologic treatment</title><author>AlBloushi, Abdulrahman F ; Alfawaz, Abdullah M ; Abu El Asrar, Ahmed M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b537t-8f1d2767cd8ecef7ecb09923021ce9da193d915601f160ea59dd99d913c592f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Biological products</topic><topic>Body mass index</topic><topic>Clinical Science</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Disease transmission</topic><topic>immunology</topic><topic>infection</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Medical supplies</topic><topic>Monoclonal antibodies</topic><topic>Ophthalmology</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Sarcoidosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>AlBloushi, Abdulrahman F</creatorcontrib><creatorcontrib>Alfawaz, Abdullah M</creatorcontrib><creatorcontrib>Abu El Asrar, Ahmed M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>AlBloushi, Abdulrahman F</au><au>Alfawaz, Abdullah M</au><au>Abu El Asrar, Ahmed M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Implications of COVID-19 infection on patients with uveitis under biologic treatment</atitle><jtitle>British journal of ophthalmology</jtitle><stitle>Br J Ophthalmol</stitle><addtitle>Br J Ophthalmol</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>106</volume><issue>11</issue><spage>1538</spage><epage>1541</epage><pages>1538-1541</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><abstract>Background/aimsTo investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.MethodsIn this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020.ResultsA total of 59 patients were identified. Behçet’s disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension.ConclusionUveitis patients under biologic therapy can be silent carriers for COVID-19.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>33931386</pmid><doi>10.1136/bjophthalmol-2020-318577</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1104-9208</orcidid><orcidid>https://orcid.org/0000-0003-2226-8617</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2022-11, Vol.106 (11), p.1538-1541 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8098233 |
| source | PubMed Central |
| subjects | Age Biological products Body mass index Clinical Science Coronaviruses COVID-19 Disease transmission immunology infection Infections Inflammation Medical supplies Monoclonal antibodies Ophthalmology Pandemics Patients Sarcoidosis |
| title | Implications of COVID-19 infection on patients with uveitis under biologic treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T22%3A13%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Implications%20of%20COVID-19%20infection%20on%20patients%20with%20uveitis%20under%20biologic%20treatment&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=AlBloushi,%20Abdulrahman%20F&rft.date=2022-11-01&rft.volume=106&rft.issue=11&rft.spage=1538&rft.epage=1541&rft.pages=1538-1541&rft.issn=0007-1161&rft.eissn=1468-2079&rft_id=info:doi/10.1136/bjophthalmol-2020-318577&rft_dat=%3Cproquest_pubme%3E2728715025%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2728715025&rft_id=info:pmid/33931386&rfr_iscdi=true |